Momenta Pharmaceuticals isn't pausing in its development of new drugs. The biotech company specializes in unpacking and engineering complex molecules in order to copy existing biologic drugs, develop complex generic drugs, and discover new drugs. Momenta's primary product is M-Enoxaparin, a generic version of Sanofi's heparin drug Lovenox. The drug received FDA approval in 2010 and was developed under an agreement with Sandoz. It is used to treat patients with deep-vein thrombosis and acute coronary syndromes. The company is also developing a generic version of biotech multiple sclerosis treatment Copaxone (marketed by Sanofi and Teva).